Tiotropium Bromide hydrateMuscarinic antagonist CAS# 139404-48-1 |
- A-867744
Catalog No.:BCC1324
CAS No.:1000279-69-5
- Rocuronium Bromide
Catalog No.:BCC1068
CAS No.:119302-91-9
- Rivastigmine
Catalog No.:BCC1900
CAS No.:123441-03-2
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 139404-48-1 | SDF | Download SDF |
| PubChem ID | 3086654 | Appearance | Powder |
| Formula | C19H22BrNO4S2 | M.Wt | 472.4 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO > 10 mM | ||
| SMILES | C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C.[Br-] | ||
| Standard InChIKey | DQHNAVOVODVIMG-CJTHRXGHSA-M | ||
| Standard InChI | InChI=1S/C19H22NO4S2.BrH/c1-20(2)12-9-11(10-13(20)17-16(12)24-17)23-18(21)19(22,14-5-3-7-25-14)15-6-4-8-26-15;/h3-8,11-13,16-17,22H,9-10H2,1-2H3;1H/q+1;/p-1/t11?,12-,13+,16+,17-; | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Tiotropium Bromide hydrate is an anticholinergic and bronchodilator and a muscarinic receptor antagonist.
Target: mAChR
Tiotropium bromide (Ba 679 BR) is a novel potent and long-lasting muscarinic antagonist that has been developed for the treatment of chronic obstructive airways disease (COPD). Binding studies with [3H]tiotropium bromide in human lung have confirmed that this is a potent muscarinic antagonist with equal affinity for M1-, M2- and M3-receptors and is approximately 10-fold more potent than ipratropium bromide. In vitro tiotropium bromide has a potent inhibitory effect against cholinergic nerve-induced contraction of guinea-pig and human airways, that has a slower onset than atropine or ipratropium bromide. tiotropium bromide dissociates slowly from M3-receptors (on airway smooth muscle) but rapidly from M2 autoreceptors (on cholinergic nerve terminals) [1]. Tiotropium bromide is a quaternary ammonium derivative that binds to muscarinic receptors. However, although tiotropium binds with high affinity to muscarinic receptors of M1-, M2- and M3-subtypes, it dissociates very slowly from M1- and M3-receptors but more rapidly from M2-receptors, thereby giving it a unique kinetic selectivity [2]. References: | |||||
Tiotropium Bromide hydrate Dilution Calculator
Tiotropium Bromide hydrate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.1169 mL | 10.5843 mL | 21.1685 mL | 42.337 mL | 52.9213 mL |
| 5 mM | 0.4234 mL | 2.1169 mL | 4.2337 mL | 8.4674 mL | 10.5843 mL |
| 10 mM | 0.2117 mL | 1.0584 mL | 2.1169 mL | 4.2337 mL | 5.2921 mL |
| 50 mM | 0.0423 mL | 0.2117 mL | 0.4234 mL | 0.8467 mL | 1.0584 mL |
| 100 mM | 0.0212 mL | 0.1058 mL | 0.2117 mL | 0.4234 mL | 0.5292 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Tiotropium bromide (Ba 679 BR) is a novel potent and long-lasting muscarinic antagonist that has been developed for the treatment of chronic obstructive airways disease (COPD). Binding studies with [3H]tiotropium bromide in human lung have confirmed that
- Guan-fu base A
Catalog No.:BCN8491
CAS No.:1394-48-5
- TC LPA5 4
Catalog No.:BCC6267
CAS No.:1393814-38-4
- KPT-330
Catalog No.:BCC4446
CAS No.:1393477-72-9
- Thiostrepton
Catalog No.:BCC7621
CAS No.:1393-48-2
- KN-93
Catalog No.:BCC1683
CAS No.:139298-40-1
- MDL 100907
Catalog No.:BCC7877
CAS No.:139290-65-6
- Zolmitriptan
Catalog No.:BCC5062
CAS No.:139264-17-8
- H2L5186303
Catalog No.:BCC6315
CAS No.:139262-76-3
- Fmoc-Lys-OH.HCl
Catalog No.:BCC3512
CAS No.:139262-23-0
- G-36
Catalog No.:BCC6283
CAS No.:1392487-51-2
- Musellarin C
Catalog No.:BCN7004
CAS No.:1392476-33-3
- Musellarin B
Catalog No.:BCN7192
CAS No.:1392476-32-2
- GNE-317
Catalog No.:BCC5655
CAS No.:1394076-92-6
- 8alpha-Hydroxyhirsutinolide
Catalog No.:BCN7111
CAS No.:1394156-45-6
- Boc-Cysteinol(Bzl)
Catalog No.:BCC3043
CAS No.:139428-96-9
- 6-O-apiosyl-5-O-Methylvisammioside
Catalog No.:BCN7858
CAS No.:139446-82-5
- Methyl 2-(((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)amino)-3-nitrobenzoate
Catalog No.:BCC9033
CAS No.:139481-28-0
- Ethyl 2-ethoxy-1-[(2'-cyanobiphenyl-4-yl)methyl]-1H-benzimidazole-7-carboxylate
Catalog No.:BCC8970
CAS No.:139481-41-7
- Methyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate
Catalog No.:BCC9032
CAS No.:139481-44-0
- Candesartan ethyl ester
Catalog No.:BCC8901
CAS No.:139481-58-6
- Candesartan
Catalog No.:BCC2558
CAS No.:139481-59-7
- Candesartan methyl ester
Catalog No.:BCC8902
CAS No.:139481-69-9
- Trityl candesartan
Catalog No.:BCC9187
CAS No.:139481-72-4
- GSK J5
Catalog No.:BCC6264
CAS No.:1394854-51-3
Tiotropium bromide inhibits TGF-beta-induced MMP production from lung fibroblasts by interfering with Smad and MAPK pathways in vitro.[Pubmed:20856827]
Int J Chron Obstruct Pulmon Dis. 2010 Sep 7;5:277-86.
BACKGROUND: chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation and structural alterations (ie, tissue remodeling) throughout the conducting airways, parenchyma, and pulmonary vasculature. Matrix metalloproteinases (MMPs) are extracellular degrading enzymes that play a critical role in inflammatory cell infiltration and tissue remodeling, but the influence of the agents that are used for the treatment of COPD on the production of MMPs is not well understood. PURPOSE: the present study aimed to examine the influence of Tiotropium Bromide hydrate (TBH) on the production of MMPs from lung fibroblasts (LFs) induced by transforming growth factor (TGF)-beta in vitro. METHODS: LFs, at a concentration of 5 x 10(5) cells.mL(-1), were stimulated with TGF-beta in the presence of various concentrations of TBH. MMP-1 and MMP-2 levels in culture supernatants were examined by enzyme-linked immunosorbent assay (ELISA), and MMP messenger ribonucleic acid (mRNA) expression was examined by real-time polymerase chain reaction (RT-PCR). The influence of TBH on TGF-beta signaling pathways was also analyzed by examining Smad activation and signaling protein phosphorylation by ELISA. RESULTS: TBH at more than 15 pg.mL(-1) inhibited the production of MMP-1 and MMP-2, but not tissue inhibitor of matrix metalloproteinase (TIMP)-1 and TIMP-2, from LFs, after TGF-beta stimulation. TBH also suppressed MMP mRNA expression through the inhibition of Smad activation and signaling protein, extracellular-signal-regulated kinase (ERK) 1 and 2, and c-Jun N-terminal kinase (JNK), phosphorylation. CONCLUSION: These results may suggest that TBH suppresses MMP production from LFs, through interference of TGF-beta-mediated signaling pathways and results in favorable modification of the clinical status of COPD.
Suppressive activity of tiotropium bromide on matrix metalloproteinase production from lung fibroblasts in vitro.[Pubmed:19281093]
Int J Chron Obstruct Pulmon Dis. 2008;3(4):781-9.
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is characterized by airway remodeling with an accumulation of inflammatory cells. There is also increasing evidence that metalloproteinases (MMPs) may contribute to the pathogenesis of COPD, but the influence of agents that used for the treatment of COPD is not well understood. OBJECTIVE: We evaluated whether Tiotropium Bromide hydrate (TBH), a M3 muscarinic receptor antagonist, could inhibit MMP production from lung fibroblasts (LFs) in response to tumor necrosis factor (TNF)-alpha stimulation. METHODS: LFs were established from normal lung tissues taken from patients with lung tumors. LFs (5 x 10(5) cells/ml) were stimulated with TNF-alpha in the presence of various concentrations of TBH. After 24 h, culture supernatants were obtained and assayed for the levels of MMPs and tissue inhibitor of metalloproteinases (TIMPs) by ELISA. The influence of TBH on mRNA expression of MMPs and TIMPs in 4h-cultured cells was also examined by real-time RT-PCR. Furthermore, nuclear factor-kappaB (NF-kappaB) and activator protein-1 (AP-1) in LFs treated with TBH for 4h was examined by ELISA. RESULTS: TBH at more than 15 pg/ml inhibited the production of MMP-2 from LFs after TNF-alpha stimulation, whereas TIMP-1 and TIMP-2 production was scarcely affected by TBH through the suppression of both mRNA expression and transcription factor, NF-kappaB, activation in LFs induced by TNF-alpha stimulation. CONCLUSION: These results suggest that the attenuating effect of TBH on MMP-2 production from LFs induced by inflammatory stimulation may be additional beneficial therapeutic effects not directly relating to its bronchodilatory effects.
